FILANA THERAPEUTICS, INC. 8-K

What Happened
Filana Therapeutics, Inc. (FLNA) filed a Form 8-K on May 7, 2026 (Item 2.02) to announce that it issued a press release regarding its results of operations and financial condition. The press release is attached to the filing as Exhibit 99.1. The company specifies that the information is being furnished — not “filed” — under the Exchange Act and therefore is not subject to Section 18 liability or to incorporation by reference into other SEC filings.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02).
• Press release attached as Exhibit 99.1 (dated May 7, 2026).
• Disclosure is furnished, not filed — not subject to Section 18 liability and not incorporated by reference.
• The 8-K itself does not include detailed financial tables in the body of the report; investors should review the attached press release for the company’s stated operating/financial information.

Why It Matters
This 8-K signals that Filana has publicly released an update on its financial condition and operating results, which can contain material information about earnings, quarterly results, cash position, or guidance. Because the release is furnished rather than filed, the company is clarifying legal protections and incorporation limits under SEC rules. Investors should read the attached press release (Exhibit 99.1) and any subsequent SEC filings for complete, filed financial statements or formal earnings disclosures before making investment decisions.